Sally Alexandroff

• Provided outstanding service to all individuals, promoting effective, and lasting business relationships.
• Achieved successful client outcomes by identifying and addressing their unique needs and goals.
• Stayed informed on industry developments and market trends to gain competitive advantage.
• Networked with other professionals and organizations to expand contacts and opportunities.
• Maintained up-to-date knowledge of industry trends and legislative changes impacting clients'' businesses or industries.

• Medical Affairs lead of multiple Asset Strategy Teams for early pipeline assets in solid tumor being investigated in NSCLC, SCLC, GI/GU
• Provides specialist scientific strategic and operational input into external expert interactions (including multiple advisory boards); generation of clinical and scientific data; GMA functional plans, integrated evidence plans, medical educational initiatives, and publication plans; while safeguarding patient safety
• Provides strategic oversight at a disease area level in order to support asset specific strategy, as well as strategic medical input into core brand strategies to support medical/marketing activities
• Responsible for understanding the regulatory requirements related to the clinical studies and global drug development
• Assists with the scientific review, development, approval, execution, and communication of affiliate/area medical affairs activities
• Ensures management of budgets, timelines, compliance requirements

• Led a team with responsibility for scientific communications (strategy, planning and execution across global publications and global medical education) and MI/MSL activities across the Lung cancer portfolios (marketed, launch and key pipeline assets)

· Strategic portfolio approach with a focus on external and internal audiences, ensuring alignment in communication from pipeline through to marketed products

o Particular focus on disease area pipeline asset strategy, involving an innovative and extensive cross company collaboration and education to ensure early commercial uptake, aiming for success

· Broad portfolio awareness with responsibility for congress coverage in collaboration with competitive intelligence, early pipeline groups and global medical affairs, internal and external communication teams

· Active involvement in the development of the overall Lung Narrative, working directly with key team members across the organization to meaningfully incorporate all compounds in the Lung franchise (from pipeline to launch) including alignment with precision medicine

· Skilled at managing, influencing without direct authority, and delivering within a complex matrix environment

· Core member of key cross functional working groups and work across Lung Cancer in collaboration with multiple internal and external stake holders

· Close collaboration with and direction of external HCPS including study steering committees to ensure timely and accurate congress presentations and publications

· Delivery of multiple symposia at major congresses (ESMO, ELCC) and management of independent medical education to support the development and medical strategy and scientific communications narrative across portfolio assets

· Developed a complex readout-dependent multi-scenario plan (including budget forecasting) for possible outcomes in canakinumab Ph III study program in preparation for launch

· Development and external validation of scientific narratives for multiple products, development of narrated videos and podcasts to aid medical education (e.g. on MoA and unmet medical need in specific patient groups/tumor types)

· Budget management ($5M)

· Franchise responsibility for canakinumab including management, planning and execution of publication strategy, coordination, planning and execution of global medical education strategy and accountability for Steering Committee liaison

• Development of detailed communication and publication plan including scenario planning for upcoming Phase III study data readouts
• Development and execution of global medical education activities, including scientific events (congress symposia, virtual expert forum, meet the expert event)
• Delivery of branding for all Lung deliverables split by Pro-Tumor Inflammation (PTI) and targeted therapy
• Have quickly established strong working relationships and collaborations with key internal and external stake holders
• Responsible for analysis and distribution of congress scientific communications including data interpretation of internal trial results and key competitor data in collaboration with key stakeholders
• Developing global communications and education for canakinumab and Pro Tumor Inflammation (PTI)
• 
  

September 2019 to April 2020: Novartis Oncology

Associate Director, Scientific Communications, Jakavi

• Responsible for all aspects of scientific communications for Jakavi (a JAK1 and JAK-2 inhibitor for MF and PV) and delivery of a NEJM manuscript externalizing key data
• Strategic leadership of COVID-19 Jakavi publication activities including leading the publication strategy for RUXCOVID for which I received a gold OMA award.
• Provided cover for capmatinib publication strategy including delivery of NEJM manuscript

• Successful, professional and effective working relationship with alliance partner Janssen (and IONIS) with responsibility for regular key presentations and elevation and resolution of disputes
• Responsible for the development of the Bayer Global Cardiovascular Publication Strategy, including early phase assets, pre-launch drugs, and all indications for Xarelto.
• Shaped an aligned publication strategy with multiple stake-holders which required a strategic overview, highly tuned interpersonal skills, and considered and appropriate decision making in response to clinical trial results/timelines and the changing external landscape.
• Led a small team responsible for the development of Bayer Global Thrombosis publication strategy, ensuring alignment with all internal stakeholders and the external alliance partner. Ensured the publication strategy was aligned with scientific objectives and the needs of local Bayer country requirements, and managed the timely delivery of all medical and scientific publications. Development and maintenance of the Strategic Publication Plan. Led and facilitated cross-functional teams to develop innovative publications strategies and plans, maintained regular interfaces with scientific/medical experts and ensured medical accuracy of all Bayer Thrombosis publications
• Core member of Bayer’s Vascular Protection Initiative, an international collaborative initiative to engage multidisciplinary stakeholders through publications, to aid the uptake and implementation of key new indications.
• Development of publication strategy in line with global strategic imperatives for both new compounds and established and new indications for Xarelto.
• Delivery of manuscripts, abstracts and posters in all areas including the growing field of Real World Evidence
• Built excellent relationships with key international external authors, SSCs and scientific experts as well as key internal stakeholders in complex matrix teams
• Effective management and relationship with medical publication communication agencies (including invoice tracking and forecasting of budgets of more than E2.5M)

• Responsible for providing strategic direction for Boehringer Ingelheim Oncology franchise US publications. Represented US team interests globally to ensure alignment of global and US publication strategies and plans, and ensure compliance with all internal and external publication policies
• Developed strategic franchise-wide publication strategy for the BI Oncology franchise.
• Developed manuscripts, abstracts and posters from secondary analyses, in line with the global Oncology strategy.
• Maintained regular interfaces and building relationships with key BI personnel
• Built and maintained relationships with key external authors and scientific experts and key internal colleagues
• Efficient management of Medical Publication agencies; providing compulsory training, ensuring timely delivery of publications and accurate invoicing
• Ensured that all publication activities are compliant with all appropriate internal and external guidelines, e.g. ICMJE and GPP
• 
  

January 2013 to June 2013: Boehringer Ingelheim Pharma Inc., Manager Publication Planning, Oncology/Respiratory

• Responsible for Publication Planning in the Respiratory and Oncology therapeutic areas.
• Assisted in the delivery of the US-specific publication plan, Needs Assessment, Gap Analysis and development of publication objectives.
• Efficiently and effectively managed external agencies.
• Represented US team interests globally to ensure alignment of global and US publication strategies and plans, and ensure compliance with appropriate internal and external publications policies.
• Supported cross-functional US Product Publications Teams charged with delivering the US publication strategy and plan.
• 
  

October 2011 to January 2013: Evince Communications, Director

• Publication planning and other novel communication activities; KOL management and education; project management responsibility for coordinating a team of medical writers, copy editors and medical personnel.
• Responsible for ensuring that all clients received the best quality solution in a timely fashion
• Successful project management to build a highly motivated and cohesive team and used superior communication and negotiating skills to motivate team and satisfy clients
• Turned around an ailing client relationship to maintain account and improve output
• Prepared and presented pitches to new clients
• Built credibility and trust with internal team and external clients

• Publication planning and other novel communication activities; KOL management and education; project management responsibility for coordinating a team of medical writers, copy editors and medical personnel.
• Responsible for ensuring that all clients received the best quality solution in a timely fashion
• Successful project management to build a highly motivated and cohesive team and used superior communication and negotiating skills to motivate team and satisfy clients
• Turned around an ailing client relationship to maintain account and improve output
• Prepared and presented pitches to new clients
• Built credibility and trust with internal team and external clients